What Is Cardiogen?
Cardiogen is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson targeting cardiac muscle tissue (myocardium). It is one of the organ-specific peptide bioregulators in the Khavinson system, designed to restore normal functional activity to aging or damaged cardiomyocytes by acting as an epigenetic regulator of cardiac gene expression. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Target Tissue and Aging
The heart undergoes significant age-related changes: cardiomyocyte hypertrophy, increased fibrosis, reduced mitochondrial efficiency, and declining responsiveness to calcium signaling. These changes manifest as reduced cardiac reserve, decreased exercise tolerance, and increased vulnerability to ischemic events. Cardiogen is designed to counteract these aging-related deteriorations at the cellular level.
Research Applications
Animal studies have demonstrated improved cardiac contractility parameters, reduced fibrosis markers, and enhanced recovery from experimental ischemia in aged animals treated with Cardiogen. It is sometimes used alongside Ventfort (vascular bioregulator) in cardiovascular anti-aging protocols.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins
Khavinson, V.Kh., Lin'kova, N.S., Polyakova, V.O., Kvetnoy, I.M., Benberin, V.V., D'yakonov, M.M., Titkov, Yu.S., 2012, Bulletin of Experimental Biology and Medicine - The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats
Chalisova, N.I., Lesniak, V.V., Balykina, N.A., Urt'eva, S.A., Urt'eva, T.A., Sukhonos, Yu.A., Zhekalov, A.N., 2009, Advances in Gerontology - Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats
Levdik, N.V., Knyazkin, I.V., 2009, Bulletin of Experimental Biology and Medicine - The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats
Zakutskii, A.N., Chalisova, N.I., Ryzhak, G.A., Aniskina, A.I., Filippov, S.V., Zeziulin, P.N., 2006, Advances in Gerontology - Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging
Kheifets, O.V., Polyakova, V.O., Kvetnoy, I.M., 2010, Advances in Gerontology - Peptides and aging
Khavinson, V.Kh., 2002, Neuroendocrinology Letters - Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis
Kharoubi M, Roche F, Bézard M, 2021, ESC Heart Fail - Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis
Bézard M, Kharoubi M, Galat A, 2021, Eur J Heart Fail - Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment
Oghina S, Josse C, Bézard M, 2021, J Clin Med - Khavinson development attribution. Existing stored entry reference; Existing stored entry reference
Cardiogen is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson targeting cardiac muscle tissue (myocardium). It is one of the organ-specific peptide bioregulators in the Khavinson system, designed to restore normal functional activity to aging or damaged cardiomyocytes by acting as an epigenetic regulator of cardiac gene expression.